Skip to main
AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals (AUPH) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aurinia Pharmaceuticals is projected to experience substantial revenue growth, with risk-adjusted product revenues expected to rise from $243.7 million in 2025 to $932.3 million by 2033. The company's pipeline also includes aritinercept, which is anticipated to generate risk-adjusted revenue of $15.4 million in 2030, increasing to $281.6 million in 2033, assuming a favorable probability of launch and market penetration. Furthermore, the anticipated positive impact from the 2024 ACR LN guideline is expected to significantly enhance the growth trajectory of Lupkynis beginning in 2027.

Bears say

Aurinia Pharmaceuticals Inc. faces a challenging financial outlook due to limited revenue growth following the launch of LUPKYNIS, as recent reports indicate stagnant sales and high operational costs that may hinder profitability. The ongoing development of AUR200 introduces additional financial risks, as the company may require substantial investment with uncertain timelines for regulatory approval and market entry. Furthermore, competitive pressures in the biopharmaceutical landscape could impede market share capture, thereby negatively impacting overall financial performance.

Aurinia Pharmaceuticals (AUPH) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aurinia Pharmaceuticals (AUPH) Forecast

Analysts have given Aurinia Pharmaceuticals (AUPH) a Buy based on their latest research and market trends.

According to 4 analysts, Aurinia Pharmaceuticals (AUPH) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aurinia Pharmaceuticals (AUPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.